Named the No. 1 antibody discovery and development company by Roots Analysis, MindWalk Holdings, Corp., is an Austin, Texas-based biointelligence ecosystem and platform designer. The company blends artificial intelligence technology, deep learning, and advanced laboratory research to deliver computable, actionable solutions for complex biological problems across a myriad of drug discovery processes. MindWalk Holdings uses its unique, AI-driven platforms to empower therapeutic and anti-drug antibodies, with a focus on diagnostics, vaccines, and peptide therapeutics. The organization also works in areas of protein engineering and production.
Recognizing that no two drug discovery programs are the same, the MindWalk Holdings team designed the platform to adapt to specifically targeted molecules, modalities, and other user-defined priorities. The company has 36 years of experience in the biotech and biotherapeutics industries. Over that time, MindWalk has established a reputation for achieving novel pharmaceutical solutions through the combination of advanced AI systems and comprehensive biologics discovery. MindWalk’s LensAI earned the 2024 InterSystems Impact Award, beating out over 1,000 international biotherapeutic research projects.